Russian oil freight rates to India ease further, proposed EU curbs may reverse trend
IFreight rates for Russian oil shipments from the Baltic ports to India eased further in the period from late May to early June, thanks to high tanker availability, but the trend may reverse if Europe's proposed lower price cap comes to fruition.
The European Union has put forward a new sanction package against Russia over Ukraine and proposed to lower the Group of Seven nations' price cap on Russian crude oil to $45 a barrel from $60 a barrel.
The G7 countries and the EU, imposed the $60 cap on Russian oil in late 2022, restricting access to Western shipping and insurance services for above-cap purchases in a bid to curb Moscow's revenues.
However, as the price of Russia's flagship Urals crude has fallen below the cap, Western shipowners have been able to return to its oil market.
Urals crude price estimates in Russia's ports have stabilised below $60 per barrel since early April, allowing more Western shipping companies, primarily Greek, to resume shipping services, increasing tanker availability and putting freight rates under pressure.
By Wednesday, the cost of Urals oil loaded from the Baltic Sea port of Primorsk was about $54.72 per barrel.
The cost of shipping Urals oil from the Baltic ports, including Ust-Luga, to India fell to between $5.5 million and $5.7 million from about $6 million per one-way shipment on average in April and May, and about $8 million early in March.
Russian crude shipping rates rose sharply after a new round of U.S. sanctions on Russian energy interests unveiled in January took effect. Russian oil sellers were forced to look for new tankers to replace those hit by sanctions.
Freight rates still remain above levels in January, when the cost of shipping Russian crude from the Baltic ports to India was between $4.7 million and $4.9 million per one-way shipment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
Aurobindo Pharma, Lupin to Natco Pharma: Why is Nifty Pharma Index nosediving today? EXPLAINED
Indian pharmaceutical stocks tumbled sharply on Tuesday, June 17, after US President Donald Trump warned that tariffs on pharmaceutical imports would be imposed 'very soon.' The Nifty Pharma index slumped over 2 percent to a day's low of 21,516.95, making it the worst-performing sector of the session. This latest development triggered widespread selling, with fears of revenue disruption for Indian drugmakers heavily reliant on the US market. The primary trigger for the sell-off was President Trump's statement to reporters that his administration would soon roll out tariffs specifically targeting pharmaceutical imports. This comes just weeks after he first hinted at such a move in April. Market participants fear that Indian drugmakers, which export a significant portion of their generics and specialty medicines to the US, could be severely impacted. According to Avinash Gorakshkar, Head of Research at Profitmart Securities, key companies like Lupin, Aurobindo Pharma, Cipla, Dr. Reddy's Laboratories, and Zydus Lifesciences are expected to face considerable pressure. 'These companies derive a large chunk of their earnings from the US, and any tariff imposition could dent margins and impact future guidance,' he said. The impact was broad-based across the pharma index. Shares of Aurobindo Pharma, Lupin, and Granules India emerged as the top losers, declining over 3 percent each. Other notable losers included Natco Pharma, Laurus Labs, Divi's Labs, Sun Pharma, and Dr Reddy's Laboratories, all of which fell over 2 percent. Pharma majors like Zydus Lifesciences, Glenmark Pharma, Ajanta Pharma, Cipla, Biocon, Alkem Labs, and IPCA Laboratories also saw cuts of over 1 percent, reflecting deep investor concern. The index has now posted losses in three out of the last four trading sessions, highlighting sustained pressure in the sector. This is not the first time Trump's rhetoric has impacted pharma stocks. In early April, when he first floated the idea of pharmaceutical tariffs, markets had already reacted with concern. At the time, Trump had said, 'The pharma [tariffs] are going to be starting to come in at, I think, a level that you haven't really seen before.' The lack of clarity since then had temporarily stabilized investor sentiment, but the latest statement has reignited anxiety. Notably, Trump had previously set July 9 as the deadline for new tariffs to take effect, giving companies limited time to reassess their strategies. While pharmaceuticals were initially kept out of the general reciprocal tariff list, the latest remarks signal a policy shift that could directly impact Indian exports. The renewed trade tensions come on the heels of Trump's abrupt departure from the G7 summit in Canada and speculation around his foreign policy approach. He denied rumours of brokering a ceasefire between Israel and Iran, stating that he was 'planning something much bigger.' The pharma tariff announcement, which followed closely on the heels of that denial, may be part of a broader strategic shift ahead of the upcoming US elections. Overall, with US President Donald Trump reaffirming his intent to impose tariffs on pharmaceutical imports, Indian pharma stocks are under renewed pressure. The Nifty Pharma index's sharp decline reflects investor fears of margin compression and revenue headwinds for companies with significant US exposure. As the July 9 deadline for tariff implementation nears, volatility in the sector is expected to remain high. Investors will be closely watching for further policy signals from the US administration and guidance from impacted companies in the coming weeks. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
an hour ago
- Mint
Europe should buy from Ukraine's defence industry
YOU MAY well think that these are particularly difficult times in Ukraine. Last year's American aid package is nearly used up, and no one expects another. Russia is launching another spring offensive and pummelling Ukraine's cities from the sky. Donald Trump's efforts to secure a peace deal have not yielded even a proposed 30-day ceasefire. In fact, the mood in Kyiv is arguably more confident than it was when last year's spring offensive loomed. One big reason is that Ukraine is much less reliant on foreign kit. The country's defence industry, largely abandoned after the collapse of the Soviet Union, is once again firing on all cylinders. This year production is expected to amount to around $15bn-worth of armaments, up from just $1bn in 2022, the year Russia's full-scale invasion began. Hundreds of tech startups have joined older state-run firms in manufacturing artillery, ammunition, armoured vehicles and—above all—drones and missiles. The drones have transformed the battlefield. Churned out in their millions by newly formed Ukrainian companies, they are cheaper and often better than Western versions. Short-range drones can spot anything that moves, swooping in to take out a tank or an exposed Russian soldier. Longer-range drones and missiles can hit command centres, ammunition dumps, barracks and industrial targets. Being home-made, they are not subject to foreigners' restrictions on what can be hit. Ukrainian officials claim their troops are now killing between seven and ten Russians for every soldier they lose. So although Ukraine is still heavily outnumbered, the imbalance in manpower matters less than it did. That is why Russia has been battling for almost nine months, at gruesome cost, to take the small city of Pokrovsk (with a pre-war population of 60,000). Russia occupies around 19% of Ukraine, almost exactly the same proportion as it did at the end of 2022. No one now talks, as they used to, of an imminent Ukrainian collapse. Yet the improvement in Ukraine's battlefield fortunes would be even more striking if European governments, and the EU itself, stepped up. One way to meet Ukraine's defence needs is to send it more Europe-made kit, but that is hard because most defence companies are loth to scale up production without long-term contracts (an exception is Rheinmetall). Instead, the Europeans should spend their military-assistance money to buttress Ukraine's own defence industry. Officials say it has the capacity to produce around $35bn-worth of equipment this year, if only the government could afford to place more contracts. One option is for European governments to supply Ukraine with weapons that they buy directly from Ukrainian companies. That would allow domestic defence production to expand to the level of existing capacity, and beyond. EU governments could also encourage, with contracts or even co-investment, joint ventures between European and Ukrainian firms. That could help the country develop faster and more accurate offensive missiles, and ideally redress Ukraine's biggest remaining weakness: its desperate shortage of air-defence missile systems that can knock out incoming Russian missiles. It would also mean that Ukrainian expertise in drone warfare is shared. Contracting with Ukraine and setting up joint ventures with its firms would be a cost-effective way to mitigate the end of American assistance. Individual European countries, led by Denmark, have already started down this path. These efforts need to be built on. Give Ukrainian defence firms more money, and they will make their own tools to keep Russia at bay. Subscribers to The Economist can sign up to our Opinion newsletter, which brings together the best of our leaders, columns, guest essays and reader correspondence.
Mint
an hour ago
- Mint
More Central Banks Than Ever Plan to Build Up Their Gold Hoards
(Bloomberg) -- A record share of the world's central banks plans to accumulate more gold over the next 12 months, drawn by bullion's performance during times of crisis and protection against inflation. In a survey of 72 monetary authorities, 43% said they expected their gold reserves to increase, up from 29% a year earlier and the highest figure in eight years of data collected by the World Gold Council and YouGov. None anticipated a decline. Central banks have been one of the most important drivers of a long-running gold rally that has seen prices double since late-2022. The pace of buying doubled after the invasion of Ukraine, when the freezing of much of Russia's foreign currency holdings highlighted the appeal of bullion as a reserve asset. 'There are some pretty big moves in some of these numbers,' said Shaokai Fan, global head of central banks for the WGC, a trade body representing gold miners. 'Western countries have stopped selling and emerging market countries have started buying, they're catching up and building more gold reserves.' The overwhelming majority of respondents said they thought central bank gold reserves would increase globally over the next 12 months. The most commonly cited relevant factors for holding gold were its performance during crises, its role as a portfolio diversifier and a store of value. Central banks have been mopping up more than 1,000 tons for each of the last three years, and are set to continue that pace of buying this year, according to consultancy Metals Focus. They have been net buyers for the last 15 years, reversing net sales that drove a decade-long bear market in the 1990s. The buying helped gold overtake the euro as the second-largest asset in the reserves of the world's central banks late last year. US dollar assets, mostly Treasuries, extended a steady decline to reach 46% of global reserves. Among the factors that threaten to accelerate the decline of the US dollar's share of global reserves are the country's yawning fiscal deficits, confiscation risk and speculation that foreign creditors may be treated less favorably. All that stands to benefit gold. More than half of the central banks from emerging economies in the survey said that gold's lack of political risk was a relevant factor behind their decision to hold gold, while 78% cited its lack of default risk. But the US dollar is not in danger of losing its status as the dominant reserve asset anytime soon. 'Central banks are looking at the dollar and the Treasury market with a little bit more care than they would earlier on,' Fan said. 'But I don't think that this is a sort of mad rush for the doors.' More stories like this are available on
